Tested batch: EP-260428-SX10
Semax is a synthetic peptide derived from ACTH (Dolotov et al., 2006). Each box contains 10 vials of lyophilized powder, with 10mg per vial. This peptide is supplied as a research compound for laboratory use only.
Specifications: SKU SX10 · 10 vials of lyophilised powder per box · 10mg per vial · measured net content 10.58 mg. Testing: four Kovera Labs reports for batch EP-260428-SX10: RP-HPLC purity 99.677% with LC-MS identity, endotoxin < 0.20 EU/mL, heavy metals and sterility – see the certificates below. Further reading: Semax in Australia: product overview and Semax: a research guide to evaluating suppliers. For laboratory research use only; not for human consumption.
Free shipping on all products.
This product is strictly intended for laboratory research use only. Not for human consumption. All products sold are for research purposes and should only be handled by qualified professionals in a controlled laboratory environment.
Tested batch: EP-260428-SX10 · 4 published certificates. Report library updated .
Batch EP-260428-SX10 – four Kovera Labs reports. Purity and identity: RP-HPLC purity 99.677%, net content 10.58 mg, LC-MS identity: Semax (KVR-2026-375789, 30 June 2026). Endotoxin: < 0.20 EU/mL (ENDO-KVR-2026-375789). Heavy metals: lead < 0.5, arsenic < 0.15, cadmium < 0.05 and mercury < 0.3 ppm (HM-KVR-2026-375789). Sterility: no bacterial growth (aerobic and anaerobic) and no fungi or yeast detected after a 2-day incubation (RSTER-KVR-2026-375789). Each certificate links to its Kovera Labs verification record, and the product image shows the same batch reference. For laboratory research use only.
| Test | Reported result | Report ID | Report date |
|---|---|---|---|
| Purity and Identity (COA) | Purity: 99.677 %; Net content: 10.58 mg; Identity confirmation: Semax | KVR-2026-375789 | 30 June 2026 |
| Endotoxin | Endotoxin: < 0.20 EU/mL | ENDO-KVR-2026-375789 | 30 May 2026 |
| Heavy Metals | Lead: < 0.5 ppm; Arsenic: < 0.15 ppm; Cadmium: < 0.05 ppm; Mercury: < 0.3 ppm | HM-KVR-2026-375789 | 31 May 2026 |
| Sterility testing | Bacteria (aerobic/anaerobic): No Growth; Fungi / yeast: Not Detected; Incubation period: 2 days | RSTER-KVR-2026-375789 | 30 May 2026 |
Read how to interpret and verify a Kovera Labs report or browse our testing standards and report directory.
Verify this certificate on Kovera Labs
| Reported test | Result | Stated criterion | Method, where stated |
|---|---|---|---|
| Purity | 99.677 % | — | RP-HPLC |
| Net content | 10.58 mg | — | — |
| Identity confirmation | Semax | — | LC-MS |
| Endotoxin screen | PASS | — | — |
| Microbial sterility screen | No Growth | — | — |
| Arsenic (As) screening | Negative | — | — |
| Cadmium (Cd) screening | Negative | — | — |
| Lead (Pb) screening | Negative | — | — |
| Mercury (Hg) screening | Negative | — | — |
Verify this certificate on Kovera Labs
| Reported test | Result | Stated criterion | Method, where stated |
|---|---|---|---|
| Endotoxin | < 0.20 EU/mL | ≤ 0.5 | — |
| Final determination | PASS | — | — |
Verify this certificate on Kovera Labs
| Reported test | Result | Stated criterion | Method, where stated |
|---|---|---|---|
| Lead | < 0.5 ppm | ≤ 10 | ICP-MS |
| Arsenic | < 0.15 ppm | ≤ 1.5 | ICP-MS |
| Cadmium | < 0.05 ppm | ≤ 0.5 | ICP-MS |
| Mercury | < 0.3 ppm | ≤ 3 | ICP-MS |
Verify this certificate on Kovera Labs
| Reported test | Result | Stated criterion | Method, where stated |
|---|---|---|---|
| Bacteria (aerobic/anaerobic) | No Growth | — | — |
| Fungi / yeast | Not Detected | — | — |
| Incubation period | 2 days | — | — |
| Temperature | 30-35C | — | — |
| Final determination | SAMPLE PASSES STERILITY SCREEN | — | — |
Evidence reviews and laboratory guides relevant to Semax 10mg, plus the testing behind each batch.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the adrenocorticotropic hormone fragment ACTH(4-10) (Dolotov et al., 2006). The studies cited here come from groups at the Institute of Molecular Genetics, Russian Academy of Sciences (Dolotov et al., 2006; Medvedeva et al., 2014).
Published Semax studies have mainly used rat models. A 2006 study measured BDNF and trkB expression in the rat hippocampus after a single administration (Dolotov et al., 2006), and a 2014 genome-wide study measured gene-expression changes in a rat model of focal brain ischaemia (Medvedeva et al., 2014). These are animal gene- and protein-expression findings; they do not show effects in people.
About the evidence. Findings reported in published studies relate to the materials used in that work. This product is supplied by Eternal Peptides Wholesale for laboratory research use only and is not for human or veterinary use. Its Kovera Labs reports are published on this page and in the COA library.
Further reading: Semax neuroscience research: evidence review
Explore Semax research, Australian buying guides and laboratory documentation.
